Inactive Instrument

bioMérieux Share Price Euronext Paris

Equities

FR0010096479

Medical Equipment, Supplies & Distribution

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 3.9B 4.19B 350B Sales 2025 * 4.19B 4.51B 376B Capitalization 11.79B 12.68B 1,058B
Net income 2024 * 467M 502M 41.89B Net income 2025 * 527M 567M 47.28B EV / Sales 2024 * 2.96 x
Net cash position 2024 * 263M 283M 23.63B Net cash position 2025 * 444M 477M 39.79B EV / Sales 2025 * 2.71 x
P/E ratio 2024 *
25.9 x
P/E ratio 2025 *
22.9 x
Employees -
Yield 2024 *
0.87%
Yield 2025 *
1%
Free-Float 36.21%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 52 01/16/01
Chairman 50 16/04/16
Director of Finance/CFO 47 01/18/01
Members of the board TitleAgeSince
Director/Board Member 74 15/06/15
Director/Board Member 63 01/05/01
Chairman 50 16/04/16
More insiders
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows: - medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors; - industrial applications (15.6%). The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services. Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Calendar
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW